Lobe Sciences Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0014
- Today's High:
- $0.0019
- Open Price:
- $0.0014
- 52W Low:
- $0.0013
- 52W High:
- $0.185
- Prev. Close:
- $0.0014
- Volume:
- 31800
Company Statistics
- Market Cap.:
- $3.76 million
- Book Value:
- 0.008
- Revenue TTM:
- $884837
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $841556
- Profit Margin:
- 0%
- Return on Assets TTM:
- -79.03%
- Return on Equity TTM:
- -340.32%
Company Profile
Lobe Sciences Ltd had its IPO on under the ticker symbol LOBEF.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Lobe Sciences Ltd has a staff strength of 0 employees.
Stock update
Shares of Lobe Sciences Ltd opened at $0 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0 - $0, and closed at $0.
This is a +21.43% increase from the previous day's closing price.
A total volume of 31,800 shares were traded at the close of the day’s session.
In the last one week, shares of Lobe Sciences Ltd have increased by 0%.
Lobe Sciences Ltd's Key Ratios
Lobe Sciences Ltd has a market cap of $3.76 million, indicating a price to book ratio of 0.7597 and a price to sales ratio of 7.7249.
In the last 12-months Lobe Sciences Ltd’s revenue was $884837 with a gross profit of $841556 and an EBITDA of $-4112988. The EBITDA ratio measures Lobe Sciences Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Lobe Sciences Ltd’s operating margin was 0% while its return on assets stood at -79.03% with a return of equity of -340.32%.
In Q0.66666666666667, Lobe Sciences Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Lobe Sciences Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.08 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lobe Sciences Ltd’s profitability.
Lobe Sciences Ltd stock is trading at a EV to sales ratio of 5.9486 and a EV to EBITDA ratio of 1.5859. Its price to sales ratio in the trailing 12-months stood at 7.7249.
Lobe Sciences Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.17 million
- Total Liabilities
- $1.99 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Lobe Sciences Ltd ended 2024 with $1.17 million in total assets and $0 in total liabilities. Its intangible assets were valued at $1.17 million while shareholder equity stood at $-815861.00.
Lobe Sciences Ltd ended 2024 with $0 in deferred long-term liabilities, $1.99 million in other current liabilities, in common stock, $-33994434.00 in retained earnings and $0 in goodwill. Its cash balance stood at $172565.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Lobe Sciences Ltd’s total current assets stands at $478428.00 while long-term investments were $665524.00 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2024, Lobe Sciences Ltd's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Lobe Sciences Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0
- 52-Week High
- $0.185
- 52-Week Low
- $0.0013
- Analyst Target Price
- $
Lobe Sciences Ltd stock is currently trading at $0 per share. It touched a 52-week high of $0.185 and a 52-week low of $0.185. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.02 and 200-day moving average was $0.03 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 253.3% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Lobe Sciences Ltd
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines to enhance brain and mental health and wellness. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.